India PesticidesQ4 FY25

India Pesticides Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹116.27P/E: 14.2Market Cap: ₹1.3K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

No

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • India Pesticides Limited projects a revenue of around INR 1,000 crores for FY '26, with capacity utilization currently at 61%, indicating room for scaling beyond this target if demand rises.
  • The company anticipates a 15% to 20% CAGR revenue growth over the next 2-3 years, supported by capacity expansion and new product additions.
  • Export contributions are expected to remain stable around 38-40% of total revenue, with focus on a balanced product mix catering to both domestic and international markets.
  • Capacity expansions at Sandila and Hamirpur facilities will support growth, with peak revenues estimated around INR 1,100 crores from Sandila alone.
  • Growth drivers include backward integration, new product registrations in regulated markets (EU, USA, Australia), and increased formulations business, especially bulk formulations exports showing over 20% YoY growth.
  • Continuously expanding distribution network in India and improving demand from regulated export markets will fuel volume growth.

See what India Pesticides management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • India Pesticides Limited currently maintains a strong balance sheet with low debt levels (total debt increased from INR 18 crore in FY '24 to INR 52 crore in FY '25, mainly short-term borrowings expected to normalize soon).
  • The company is committed to funding all expansion and capital expenditure from internal accruals and maintaining a debt-free position.
  • Planned capex of INR 116 crore for FY '26 is funded internally, with no mention of new fundraising through debt or equity.
  • Management focus remains on operational growth and capacity expansion without plans for external fundraising.
  • There was no indication or discussion about imminent equity fundraising or debt issuance during the call.

See what India Pesticides management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Planned Capex for FY '26: INR 116 crore for India Pesticides and its 100% subsidiary Shalvis Specialities Limited.
  • Capex includes:
  • - Expansion at Sandila site (INR 52 crore portion) for increasing capacity, adding a boiler, one intermediate, and one technical product complex.
  • - New production blocks to manufacture new products not possible in existing blocks.
  • Two-year targeted capex exceeds INR 200 crore.
  • Hamirpur facility progressing well, expected to contribute to gradual revenue and profitability increase over coming years.
  • Capex funded primarily through internal accruals, maintaining a debt-free position.
  • Strategic efforts include backward integration to improve margins, ramping up production, and diversifying product portfolio.
  • Exploration under CRDMO initiative to collaborate with international companies for scaling research products commercially.

Track India Pesticides — get its next earnings analysis in your feed

How does India Pesticides rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisIndia Pesticides
Rev 3Mar 1

How does India Pesticides rank in Fertilizers & Agrochemicals?

Compare India Pesticides against every Fertilizers & Agrochemicals company (Q4 FY25) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →